Halcyon 4.0 imaging for Malignant Neoplasm of Colon

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Washington University School of Medicine, Saint Louis, MO
Malignant Neoplasm of Colon+6 More
Halcyon 4.0 system - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This prospective imaging study is evaluating the feasibility of using the Halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer. The Halcyon 4.0 system has been engineered to decrease the image acquisition time and the radiation exposure, but the system has not yet been clinically validated for use in radiation planning. This pilot study will evaluate images obtained on the Halcyon 4.0 system to assess if the quality is sufficient for radiation treatment plan construction.

Eligible Conditions

  • Malignant Neoplasm of Colon
  • Ovarian Cancer
  • Head and Neck Cancer
  • Cancer Brain
  • Malignant Neoplasm of Stomach
  • Lung Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: At 9 weeks

At 9 weeks
Percentage of images that are of sufficient quality for patient primary treatment plan construction

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Halcyon 4.0 imaging
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Halcyon 4.0 imaging · No Placebo Group · N/A

Halcyon 4.0 imaging
Device
Experimental Group · 1 Intervention: Halcyon 4.0 system · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 9 weeks
Closest Location: Washington University School of Medicine · Saint Louis, MO
Photo of washington university school of medicine  1Photo of washington university school of medicine  2Photo of washington university school of medicine  3
2004First Recorded Clinical Trial
7 TrialsResearching Malignant Neoplasm of Colon
1465 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.
A negative pregnancy test must be obtained
You are able to understand and willing to sign an IRB approved written informed consent document.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.